glp-1 class action in michigan side effect attorney James Boyd, a lawyer at Siskinds LLP, shares insights on a proposed class action targeting drugs Consumer Class Actions Sparked by

PMID: 38675421

December 2, 2025: Modest Growth for Ozempic Gastroparesis MDL There are now 2,947 active lawsuits in the MDL focused on claims involving GLP-1 drugs and intestinal conditions like gastroparesis

Researchers found that fucoxanthin supplementation could play a beneficial role in antiobesity through various pathways (Figure 3)

Sn phm c chng minh an ton khi s dng nhiu ln v lu di

Plaintiffs in the growing litigation over GLP-1 medications like Ozempic, Wegovy, and Mounjaro have asked a federal judge to reject efforts by Novo Nordisk and Eli Lilly to dismiss most of the claims brought against them

This limitation was addressed by the obesity-only analyses we conducted of patients with no claims history of diabetes